After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
Myler has spent his over 25-year career advising vertical software clients in buy- and sell-side M&A, IPO, private capital raising and debt capital markets transactions.
Drugmakers have been focused on buying late-stage assets with larger revenue potential to replace older blockbuster drugs that have fallen out of favor.
Karuna Therapeutics has a schizophrenia treatment, KarXT, that’s up for approval in the U.S. and would expand Bristol Myers’s portfolio in neuroscience.
December 22, 2023
Join our Membership
Join the Merger & Acquisitions community to access premium content and exclusive member-only benefits.